NASDAQ Biotech Market Gainers; (BPAX), (CELG), (GILD) Stocks to Watch

Point Roberts, WA –November 2, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the NASDAQ's market gainers in today's trading.. Gilead Sciences Inc. GILD up 0.05 (0.10%) on over 3.5 million shares. Biotech /Pharma Sector Trading Snapshot: (as of time of release November 2nd) BioSante Pharmaceuticals, Inc. BPAX trading at $1.52, up 0.02 (1.33%) Celgene Corporation CELG trading at $62.95, up 1.05 (31.70%) Gilead Sciences Inc. GILD trading at $ 40.29, up 0.05 (0.10%) on over 3,511,673 million shares NASDAQ Biotechnology Index Index Value Net Change High Low 927.10 3.15+ 931.30 923. Market Summary Dow 11,201.59 +76.97 +0.69% Nasdaq 2,529.10 +24.26 +0.97% S&P 500 1,193.75 +9.37 +0.79% 10 Yr Bond(%) 2.5940% -0.0340 Oil 84.25 +1.30 +1.57% Gold 1,355.80 +5.60 +0.41% Biotech/Pharma Stocks Recent News; BioSante Pharmaceuticals, Inc. BPAX Investor Fact Sheet update and News: BioSante Pharmaceuticals, Inc. BPAX Reports Positive LibiGel® Data Monitoring Committee Recommendation No safety issues observed, study to continue as per protocol without modifications LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. BPAX today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf Financial Highlights • At September 30, 2010, BioSante had approximately $36M in cash • Monthly burn rate of approximately $3.5M Investment Highlights • Financial resources to implement plan • Late stage pharmaceutical product portfolio with significant growth potential • LibiGel in three ongoing Phase III safety and efficacy clinical studies • Elestrin is FDA approved and marketed in the U.S. • Proprietary cancer vaccines in Phase II clinical trials • Focused growth strategy • Management's proven ability to gain FDA approval, implement plans and increase stockholder value More news - Visit the BPAX showcase profile at Investorideas.com http://www.investorideas.com/CO/BPAX/ Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com Gilead Sciences Inc. GILD News: Viread® for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment “Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection. Significantly, no resistance to Viread emerged over 192 weeks of treatment, and 10.8 percent of patients receiving Viread in Study 103 (HBeAg-positive) for four years experienced surface, or “s”, antigen (HBsAg) loss, which is a marker of the resolution of chronic HBV infection. Additional data from these studies and from Study 106 show the durable antiviral efficacy of Viread among several key patient subpopulations, including patients with high baseline viral levels, individuals of Asian descent and treatment-experienced patients. These findings are being presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2010) in Boston.” Full Article: http://finance.yahoo.com/news/Viread-for-Hepatitis-B-bw-2871028130.html?x=0&.v=1 About Gilead Sciences, Inc: Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp About InvestorIdeas.com: InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires. Sign up for free stock alerts on biotech stocks and other leading sectors! http://www.investorideas.com/Resources/Newsletter.asp About our Biotech investor portal: www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories. Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising. More info: Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp C Van Zant: 800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com